TSE:4502Pharmaceuticals
Takeda (TSE:4502) Valuation in Focus After Landmark RICO Class Action Ruling
This week, Takeda Pharmaceutical (TSE:4502) finds itself in the spotlight after the Ninth Circuit affirmed class certification in a landmark civil RICO lawsuit involving its diabetes drug, Actos. This ruling could bring major financial consequences and reshape legal expectations across the pharmaceutical sector.
See our latest analysis for Takeda Pharmaceutical.
Takeda’s share price has seen solid momentum lately, with a 7.5% gain over the past month and a 7.3% year-to-date increase, even as...